Octreotide
Also known as: Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
FDA-approved synthetic somatostatin analog for hormone-related indications.
Status
FDA Approved
Typical dose
100–500mcg
Researched for
Acromegaly, carcinoid tumors, hormone regulation
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
FDA approved - FDA-approved for specific uses with established human evidence
Use the tools
Stay current
Get updates on Octreotide
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Synthetic eight-amino-acid somatostatin analog.
- Source status: FDA Approved, with multiple listed indications.
- Reported use areas include acromegaly, carcinoid tumors, and hormone regulation.
- Source dosing entries describe immediate-release use and monthly long-acting depot use.
- Reported adverse effects include gastrointestinal symptoms, gallstones, bradycardia, glucose changes, hypothyroidism, and pancreatitis.
How it's thought to work
Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow.
What the research shows
Where the research stands
The supplied evidence characterizes Octreotide as a well-studied drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar.
What it shows
✓ Human clinical evidence
FDA-approved for specific uses with established human evidence
△ Limitations
Use only according to approved labeling and qualified medical guidance.
Bottom line: FDA Approved - Multiple indications FDA Approved
Typical dosing
CommunityCommunity dataset100–500 mcg
SC 2-3x daily or LAR monthly
Community-reported dosing information is presented for context only; the source associates octreotide with acromegaly and carcinoid tumor indications. · Subcutaneous or intramuscular depot
Research dosing
Indication-specificApproved for specific uses - study doses are indication-specific
Timing & administration
Best time to take
Morning or as directed
Follow recommended protocol
Food recommendation
With or without food
Why this timing?
The source does not establish one universal administration time; it indicates that consistent use and protocol-specific timing matter more than a fixed clock time.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Nausea
- Diarrhea
- Abdominal pain
- Gallstones
- Bradycardia
- Hyperglycemia or hypoglycemia
- Hypothyroidism
- Pancreatitis
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Frequently asked questions
Sequence
H-D-Phe-Cys(1)-Phe-D-Trp-Lys-Thr-Cys(1)-Thr-ol; Cys2-Cys7 disulfide
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.